. 2015 Nov 26;16(12):28126–28145. doi: 10.3390/ijms161226087

Table 7.

Comparison of the treatment outcome of lamivudine and entecavir in chronic hepatitis B with severe acute exacerbation.

Authors	Design	Treatment (Patient Number)	HBV DNA (Log copies/mL)	Mortality (%)	p-Value	Prognostic Factors
Cui et al. [70]	Retrospective study	ETV (33)	5.9	51.5%	0.72	Age
		LMV (34)	5.9	50%		cholinesterase
		LMV (34)	5.9	50%		MELD score
Chen et al. [61]	Retrospective study	ETV (42)	6.4	51.5%	0.374	Bilirubin
		LMV (30)	5.6	50%		Cholesterol
		LMV (30)	5.6	50%		Prothrombin activity MELD-Na score
Lai et al. [71].	Retrospective study	ETV (93)	6.4	51.5%	0.680	Bilirubin
		LMV (89)	5.6	50%		Creatinine
		LMV (89)	5.6	50%		Prothrombin time MELD score
Liu et al. [72]	Retrospective study	ETV (31)	6.2	0%	0.385	N/A
Liu et al. [72]	Retrospective study	LMV (34)	7.0	3%	0.385	N/A
Zhang et al. [73]	Retrospective study	ETV (65)	7.0	21.5%	0.066	Gender
						HBeAg(+)
						MELD score
						Child–Pugh scores
		LMV (54)	7.2	35.2%		Undetectable HBV at 30 days
Chen et al. [74]	Retrospective study	ETV (107)	6.5	21.2%	0.02	MELD score
		LMV (215)	6.5	12.3%		Ascites
		LMV (215)	6.5	12.3%		Hepatic enceophalopathy
Wong et al. [75]	Retrospective study	ETV (36)	7.3	19%	0.010	Prothrombin time
Wong et al. [75]	Retrospective study	LMV (117)	7.6	4%	0.010	ETV treatment
Tsai et al. [76]	Retrospective study	ETV (40)	8.3	12.5%	0.035	Prothrombin time
Tsai et al. [76]	Retrospective study	LMV (59)	8.4	1.7%	0.035	ETV treatment
Ye et al. [77]	Meta-analysis	ETV (423)	N/A	6.4%	NS	N/A
Ye et al. [77]	Meta-analysis	LMV(450)	N/A	7.9%	NS	N/A
Yu et al. [65]	Meta-analysis	ETV (192)	N/A	36.4%	0.35	N/A
Yu et al. [65]	Meta-analysis	LMV (148)	N/A	40.5%	0.35	N/A

ETV: entecavir; LMV: lamivudine; MELD: the model for end-stage liver disease; HBeAg: hepatitis B e antigen; N/A: not analyzed; NS: non-significant.